Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

53.2K
Overview
53.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2024/25 end-of-season KP.2 vaccine effectiveness against COVID-19 hospitalization in older adults: a test-negative study in Quebec, Canada.

Vaccine·2026
Same author

Interim 2025/26 LP.8.1 vaccine effectiveness estimates against COVID-19 from the Canadian Sentinel Practitioner Surveillance Network (SPSN): insights into possible impact of influenza and other respiratory virus co-circulation.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026
Same author

AMMI Canada seasonal influenza guideline update 2025-26: Some questions answered.

Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada·2026
Same author

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
Same author

Emergence of seasonal influenza A(H3N2) variants with immune escape potential warrants enhanced molecular and epidemiological surveillance for the 2025-2026 season.

Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada·2026
Same author

Population immunity to clade 2.3.4.4b H5N1 is dominated by anti-neuraminidase antibodies.

mBio·2026

Related Experiment Video

Updated: Mar 16, 2026

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

38.3K

Repeat Influenza Vaccination and High-Dose Efficacy

Danuta M Skowronski1, Catharine Chambers1, Rodica Gilca2

  • 1BC Centre for Disease Control, Vancouver, British Columbia.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|August 11, 2016
PubMed
Summary

No abstract available in PubMed .

More Related Videos

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

8.2K
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

8.7K

Related Experiment Videos

Last Updated: Mar 16, 2026

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

38.3K
A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

8.2K
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

8.7K